Trial Profile
A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Cluster headache
- Focus Adverse reactions
- Acronyms ENFORCE
- Sponsors Teva Branded Pharmaceutical Products R&D
- 21 Jan 2022 This trial has been completed in Finland (Date of the global end of the trial : 11-Jun-2019), according to European Clinical Trials Database record.
- 13 Mar 2020 This trial has been completed in Netherland (Global End Date: 23 Apr 2019), according to European Clinical Trials Database record.
- 10 May 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.